MedTrace Logo

A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber

NCT00420082 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2012-04-05

No results posted yet for this study

Summary

This is a randomized, double blind, active and placebo controlled, 4 way crossover study in patients with seasonal allergic rhinitis. Patients will receive a single dose of bilastine 20 mg, Cetirizine 10 mg, Fexofenadine 120 mg, and placebo in the Vienna Challenge Chamber.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

DRUG

Bilastine

Encapsulated Bilastine 20 mg tablets Q.D.

DRUG

Fexofenadine

Encapsulated Fexofenadine 120 mg tablets Q.D.

DRUG

Cetirizine

Encapsulated Cetirizine 10 mg tablets Q.D.

DRUG

Placebo

Encapsulated Placebo tablets Q.D.

Sponsors & Collaborators

  • Faes Farma, S.A.

    lead INDUSTRY

Principal Investigators

  • Friedrich Horak, Professor · ENT University Clinic Vienna

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Completion
2006-12-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00420082 on ClinicalTrials.gov